Ms Paula Byrne:

Yes, that is an opinion. I wish to go back to the base material and licensing information.

It was given to the FDA by the manufacturers of this vaccine. The final conclusions on this brought together all the trial results. The combined impact of Gardasil in the incidence of CIN - the precancerous lesions - irrespective of HPV type, range from a high of 45.5% to a low of 11.2%. In my view, as a parent, this leaflet says that it gives 100% protection from cervical cancer. It also concludes I am protected now for life. From a parent's perspective this is not 45% or 11%, but rather it is 100% protection. My biggest problem is with the data from the trials.